Skip to main content

Advertisement

SpringerLink
Log in

Medical Management of Patients With Brain Tumors

  • Neuro-oncology (Neoplasms)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Patients with brain tumors require meticulous attention to medical issues resulting from their disease or its therapy. The following specific issues are the ones most frequently arising in the purview of neurologists: (1) Vasogenic edema: Corticosteroids should be used in divided doses in the minimum amount required to control symptoms and should be tapered as quickly as possible. Some patients may require long-term steroid supplementation, and symptoms of adrenal insufficiency should be investigated with 8 am cortisol measurement and treated with appropriate repletion. (2) Seizures: Patients with brain tumors should receive antiepileptic drugs only if they have had seizures, and the drugs should be chosen to minimize cognitive effects and interactions with concurrently administered chemotherapy. Levetiracetam is an excellent choice for patients with partial seizures and is available both orally and parenterally. Lamotrigine is another reasonable choice but requires slow titration. (3) Venous thromboembolism: All brain tumor patients should receive perioperative venous thrombosis prophylaxis with compression boots and enoxaparin or dalteparin. Lifelong treatment with low molecular weight heparinoids or warfarin is required for those developing venous thromboembolism. (4) Other problems: Long-term survivors of brain tumors should be monitored indefinitely for cognitive problems, endocrine dysfunction, and development of secondary neoplasms. Modafinil can improve mood and attention impairments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Catt S, Chalmers A, Fallowfield L. Psychosocial and supportive-care needs in high-grade glioma. Lancet Oncol. 2008;9(9):884–91.

    Article  PubMed  Google Scholar 

  2. Wenger NS, Vespa PM. Ethical issues in patient-physician communication about therapy for cancer: professional responsibilities of the oncologist. Oncologist. 2010;15 Suppl 1:43–8.

    Article  PubMed  Google Scholar 

  3. Wilson JF. Cancer care: a microcosm of the problems facing all of health care. Ann Intern Med. 2009;150(8):573–6.

    PubMed  Google Scholar 

  4. Keating NL, Landrum MB, Rogers Jr SO, et al. Physician factors associated with discussions about end-of-life care. Cancer. 2010;116(4):998–1006.

    Article  PubMed  Google Scholar 

  5. Pace A, Metro G, Fabi A. Supportive care in neurooncology. Curr Opin Oncol 2010; 22(6):621–626.

    Article  PubMed  Google Scholar 

  6. Batchelor TT, Byrne TN. Supportive care of brain tumor patients. Hematol Oncol Clin North Am. 2006;20(6):1337–61.

    Article  PubMed  Google Scholar 

  7. Watling CJ, Cairncross JG. Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three cases. J Neurosurg. 2002;97(1):224–6.

    Article  PubMed  CAS  Google Scholar 

  8. Vecht CJ, Hovestadt A, Verbiest HBC, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology. 1994;44:675–80.

    PubMed  CAS  Google Scholar 

  9. Meyer G, Badenhoop K. Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy. Med Klin (Munich). 2003;98(5):266–70.

    Article  Google Scholar 

  10. Nielsen GL, Sorensen HT, Mellemkjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med. 2001;111(7):541–5.

    Article  PubMed  CAS  Google Scholar 

  11. Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol. 2003;63(3):263–70.

    Article  PubMed  Google Scholar 

  12. Kovacs JA, Gill VJ, Meshnick S, et al. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA. 2001;286(19):2450–60.

    Article  PubMed  CAS  Google Scholar 

  13. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348(8):727–34.

    Article  PubMed  CAS  Google Scholar 

  14. Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA. 2002;287(2):236–40.

    Article  PubMed  CAS  Google Scholar 

  15. Wood GJ, Shega JW, Lynch B, et al. Management of intractable nausea and vomiting in patients at the end of life: “I was feeling nauseous all of the time. .. nothing was working”. JAMA. 2007;298(10):1196–207.

    Article  PubMed  CAS  Google Scholar 

  16. Lee JW, Bromfield EB, Kesari S. Antiemetic properties of the antiepileptic drug levetiracetam. N Engl J Med. 2008;359(17):1853.

    Article  PubMed  CAS  Google Scholar 

  17. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886–93.

    PubMed  CAS  Google Scholar 

  18. van Breemen MS, Rijsman RM, Taphoorn MJ, et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009;256(9):1519–26.

    Article  PubMed  Google Scholar 

  19. Mamon HJ, Wen PY, Burns AC, et al. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia. 1999;40(3):341–4.

    Article  PubMed  CAS  Google Scholar 

  20. Mattson RH. Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use. Rev Neurol Dis. 2004;1 Suppl 1:S10–7.

    PubMed  Google Scholar 

  21. Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 2008; 71(9):665–669.

    Article  PubMed  CAS  Google Scholar 

  22. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14(12):1722–6.

    Article  PubMed  CAS  Google Scholar 

  23. Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355(9198):134–8.

    Article  PubMed  CAS  Google Scholar 

  24. Weiger WA, Smith M, Boon H, et al. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med. 2002;137(11):889–903.

    PubMed  Google Scholar 

  25. Wen PY, Schiff D, Kesari S, et al. Medical management of patients with brain tumors. J Neurooncol. 2006;80(3):313–32.

    Article  PubMed  CAS  Google Scholar 

  26. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr Opin Pulm Med. 2001;7(5):326–31.

    Article  PubMed  CAS  Google Scholar 

  27. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000;89(3):640–6.

    Article  PubMed  CAS  Google Scholar 

  28. Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009;27(29):4865–73.

    Article  PubMed  CAS  Google Scholar 

  29. Perry JR. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents. Curr Opin Neurol. 2010;23(6):592–6.

    Article  PubMed  CAS  Google Scholar 

  30. Drappatz J, Wong ET, Schiff D, et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;73(1):222–7.

    Article  PubMed  CAS  Google Scholar 

  31. Jenkins EO, Schiff D, Mackman N, et al. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010; 8(2):221–227.

    Article  PubMed  CAS  Google Scholar 

  32. Nghiemphu PL, Green RM, Pope WB, et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro-Oncology. 2008;10(3):355–60.

    Article  PubMed  Google Scholar 

  33. Streiff MB. Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol. 2009;27(29):4889–94.

    Article  PubMed  Google Scholar 

  34. Lyman GH, Khorana AA, Falanga A, et al. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490–505.

    Article  PubMed  CAS  Google Scholar 

  35. Knovich MA, Lesser GJ. The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol. 2004;5(6):511–7.

    Article  PubMed  Google Scholar 

  36. Cesarone MR, Belcaro G, Nicolaides AN, et al. Venous thrombosis from air travel: the LONFLIT3 study—prevention with aspirin vs. low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology. 2002;53(1):1–6.

    Article  Google Scholar 

  37. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8(9):1959–1965.

    Article  PubMed  CAS  Google Scholar 

  38. Chan AT, Atiemo A, Diran LK, et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis. 1999;8(2):139–42.

    Article  PubMed  CAS  Google Scholar 

  39. Triebel KL, Martin RC, Nabors LB, et al. Medical decision-making capacity in patients with malignant glioma. Neurology. 2009;73(24):2086–92.

    Article  PubMed  Google Scholar 

  40. Hickok JT, Roscoe JA, Morrow GR, et al. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer. 2005;104(8):1772–8.

    Article  PubMed  Google Scholar 

  41. Pelletier G, Verhoef MJ, Khatri N, et al. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol. 2002;57(1):41–9.

    Article  PubMed  Google Scholar 

  42. Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16(7):2522–7.

    PubMed  CAS  Google Scholar 

  43. Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116(14):3513–20.

    Article  PubMed  CAS  Google Scholar 

  44. Shaw EG, Rosdhal R, D’Agostino Jr RB, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006;24(9):1415–20.

    Article  PubMed  CAS  Google Scholar 

  45. Pruitt A, Dalmau J, Detre J, et al. Episodic neurologic dysfunction with migraine and reversible imaging findings after radiation. Neurology. 2006;67(4):676–8.

    Article  PubMed  CAS  Google Scholar 

  46. Grimm SA, Yahalom J, Abrey LE, et al. Retinopathy in survivors of primary central nervous system lymphoma. Neurology. 2006;67(11):2060–2.

    Article  PubMed  Google Scholar 

  47. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82.

    Article  PubMed  CAS  Google Scholar 

  48. Al-Mefty O, Topsakal C, Pravdenkova S, et al. Radiation-induced meningiomas: clinical, pathological, cytokinetic, and cytogenetic characteristics. J Neurosurg. 2004;100(6):1002–13.

    Article  PubMed  Google Scholar 

  49. El-Jawahri A, Podgurski LM, Eichler AF, et al. Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. J Clin Oncol 2010; 28(2):305–310.

    Article  PubMed  Google Scholar 

  50. Kaal ECA, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol. 2004;16:593–600.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Neurology, University of Pennsylvania, 3 West Gates, 3400 Spruce Street, Philadelphia, PA, 19104, USA

    Amy A. Pruitt MD

Authors
  1. Amy A. Pruitt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy A. Pruitt MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pruitt, A.A. Medical Management of Patients With Brain Tumors. Curr Treat Options Neurol 13, 413–426 (2011). https://doi.org/10.1007/s11940-011-0132-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-011-0132-y

Keywords

Search

Navigation